Wafik El-Deiry, Director of Legorreta Cancer Center at Brown University and Chair of the WIN Consortium in Cancer Personalized Medicine, shared a post on X:
“Important presentation at GI26 highlighting new guidance to test all patients who are planned to receive a fluoropyrimidine to have DPYD variant testing. A long overdue change in practice that makes sense to reduce toxicities including risk of fatal toxicities.
Reminder about uridine triacetate rapid reversal agent.
Capecitabine’s Black Box Warning:
Practical Considerations for DPD
Deficiency in Treatment Decisions by
Thomas Holden, MD, Stanford University Medical Center.”
You can also read: Highlights from ASCO GI 2026 by Wafik El-Deiry
